Oklahoma Society of Clinical Oncology
  • About Us
  • Membership
  • Latest News
  • Sponsorship
  • Events
  • Resources & Links

Daratumumab (DARZALEX)

By back40design
On November 22nd, 2016

U.S. Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.



No comments have been posted yet.

OSCO

P.O. Box 720024, Oklahoma City, OK 73172

1 405-850-8334 Call
  • Contact Us
  • Resources
  • Clinical Trials
  • Privacy Policy
  • Terms of Use
©2023 Oklahoma Society of Clinical Oncology. Website designed & developed by Back40 Design.